TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
NorthX Biologics AB
Closing information (x1000 NOK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
110,926
|
150,341
|
135,116 |
| Financial expenses |
214
|
746
|
421 |
| Earnings before taxes |
-74,716
|
-11,108
|
-31,048 |
| EBITDA |
-63,416
|
-4,101
|
-21,884 |
| Total assets |
363,882
|
261,461
|
215,961 |
| Current assets |
168,488
|
130,569
|
101,857 |
| Current liabilities |
316,845
|
253,988
|
213,871 |
| Equity capital |
47,037
|
7,473
|
2,090 |
| - share capital |
101
|
95
|
98 |
| Employees (average) |
145
|
129
|
124 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
12.9%
|
2.9%
|
1.0% |
| Turnover per employee |
765
|
1,165
|
1,090 |
| Profit as a percentage of turnover |
-67.4%
|
-7.4%
|
-23.0% |
| Return on assets (ROA) |
-20.5%
|
-4.0%
|
-14.2% |
| Current ratio |
53.2%
|
51.4%
|
47.6% |
| Return on equity (ROE) |
-158.8%
|
-148.6%
|
-1485.6% |
| Change turnover |
-50,083
|
19,286
|
47,771 |
| Change turnover % |
-31%
|
15%
|
55% |
| Chg. No. of employees |
16
|
5
|
20 |
| Chg. No. of employees % |
12%
|
4%
|
19% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.